Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arcturus Therapeutics (ARCT)
NASDAQ:ARCT
RESEARCH TOOLSreports
Holding ARCT?
Track your performance easily
See the Price Targets and Ratings of:
ARCT Analyst Ratings
Strong Buy
4 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ARCT Stock 12 Month Forecast
Average Price Target
$65.00
▲(293.22% Upside)
| Highest Price Target$74.00 | Average Price Target$65.00 | Lowest Price Target$58.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
Reiterated
12/17/24
Leerink Partners
Reiterated
12/13/24
Canaccord Genuity
Reiterated
12/06/24
Wells Fargo
Assigned
09/30/24
William Blair
―
Buy
―
Reiterated
09/04/24
William Blair reiterates Outperform Rating on Arcturus Therapeutics (ARCT)William Blair analyst Myles R. Minter reiterated an Outperform rating on Arcturus Therapeutics (NASDAQ: ARCT)
Piper Sandler
$140
Buy
746.94%
Upside
Assigned
08/06/24
Arcturus Therapeutics (ARCT) Receives a Buy from Piper Sandler
Laidlaw
$79
Buy
377.92%
Upside
Reiterated
07/02/24
Laidlaw reiterates Buy Rating on Arcturus Therapeutics (ARCT)Laidlaw analyst Yale Jen reiterated a Buy rating and $79.00 price target on Arcturus Therapeutics (NASDAQ: ARCT).
WBB Securities
$25
Buy
51.24%
Upside
Upgraded
06/30/24
We arrive at our valuation using a sum-of-the-parts model: We assign a per-share value of $10.00 to the Lunar-OTC program and $9.00 to the LUNAR-CF program. And the balance of $6.00 to the different vaccine programs. Thus, we arrive at a 12- month per share price target of $25.00.
Citi
$48
Buy
190.38%
Upside
Reiterated
05/29/24
Citi reiterates Buy Rating on Arcturus Therapeutics (ARCT)Citi analyst Yigal Nochomovitz reiterated a Buy rating and $48.00 price target on Arcturus Therapeutics (NASDAQ: ARCT).
Best Analysts Covering Arcturus Therapeutics
Which Analyst Should I Follow If I Want to Buy ARCT and Sell After:
1 Month
xxx
Success Rate
6/10 ratings generated profit
Average Return
+0.97%
assigned a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +0.97% per trade.
3 Months
xxx
Success Rate
5/14 ratings generated profit
Average Return
-3.81%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 35.71% of your transactions generating a profit, with an average return of -3.81% per trade.
1 Year
Success Rate
3/20 ratings generated profit
Average Return
-31.01%
assigned a buy rating 5 months ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 15.00% of your transactions generating a profit, with an average return of -31.01% per trade.
2 Years
xxx
Success Rate
4/20 ratings generated profit
Average Return
-21.87%
assigned a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 20.00% of your transactions generating a profit, with an average return of -21.87% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ARCT Analyst Recommendation Trends
Rating
Aug 24
Sep 24
Oct 24
Nov 24
Dec 24
Strong Buy
11
15
11
9
6
Buy
2
2
3
5
4
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
13
17
14
14
10
Each month's total comprises the sum of three months' worth of ratings.
ARCT Financial Forecast
ARCT Stock Forecast FAQ
What is ARCT’s average 12-month price target, according to analysts?
Based on analyst ratings, Arcturus Therapeutics’s 12-month average price target is $65.00.
What is ARCT’s upside potential, based on the analysts’ average price target?
Arcturus Therapeutics has 293.22% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ARCT a Buy, Sell or Hold?
Arcturus Therapeutics has a consensus rating of Strong Buy which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
What is Arcturus Therapeutics’s price target?
The average price target for Arcturus Therapeutics is $65.00. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $74.00 ,the lowest forecast is $58.00. The average price target represents 293.22% Increase from the current price of $16.53.
The highest analyst price target is $74.00 ,the lowest forecast is $58.00. The average price target represents 293.22% Increase from the current price of $16.53.
What do analysts say about Arcturus Therapeutics?
Arcturus Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
How can I buy shares of ARCT?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.